Temixys and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Temixys (lamivudine / tenofovir).
Tenofovir Food
Minor Food Interaction
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
Lamivudine High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Major Potential Hazard, Moderate plausibility
NRTIs - pancreatitis
The nucleoside reverse transcriptase inhibitors, didanosine, stavudine, and lamivudine, may cause pancreatitis. The incidence is generally low but is up to 7% with didanosine, and up to 18% in pediatric patients given lamivudine. Patients with a history of or known risk factors for pancreatitis (such as alcohol abuse or hypertriglyceridemia) should be monitored closely during therapy with these agents. Therapy should be discontinued at the first signs/symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.
References
- (2019) "Product Information. Epivir (lamiVUDine)." ViiV Healthcare, SUPPL-39
- (2018) "Product Information. Videx (didanosine)." Bristol-Myers Squibb, SUPPL-54
- (2018) "Product Information. Zerit (stavudine)." Bristol-Myers Squibb, SUPPL-41
Temixys drug interactions
There are 238 drug interactions with Temixys (lamivudine / tenofovir).
Temixys disease interactions
There are 7 disease interactions with Temixys (lamivudine / tenofovir) which include:
- hepatitis B
- hepatotoxicity
- pancreatitis
- renal dysfunction
- bone toxicity
- liver disease
- renal dysfunction
More about Temixys (lamivudine / tenofovir)
- Temixys consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.